SEC Form 4

FORM 4
[  ] Check this box if no longer
subject to Section 16. Form 4 or Form
5 obligations may continue.
See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005
Estimated average burden
hours per response. . . . . 0.5

1. Name and Address of Reporting Person^* Amgen Inc. (Last)                      (First)                      (Middle) One Amgen Center Drive (Street) Thousand Oaks,    CA   91320-1799 (City)                      (State)                      (Zip)
2. Issuer Name
and Ticker or Trading Symbol
Regeneron Pharmaceuticals, Inc.
(REGN) 3. I.R.S. Identification
    Number of Reporting
    Person, if an entity
    (voluntary) 4. Statement for
    (Month/Day/Year
03/14/2003
5. If Amendment,
    Date of Original
    (Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   Director   X 10% Owner    Officer (give title below)        Other (specify below)
Description           7. Individual or Joint/Group
    Filing (Check Applicable Line)
X   Form filed by One Reporting Person      Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security     (Instr. 3)	2.Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction     Code     (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D)     (Instr. 3, 4, and 5)			5. Amount of     Securities     Beneficially     Owned Following     Reported Transaction(s)     (Instr. 3 and 4)	6. Owner-     ship     Form:     Direct (D)     or     Indirect (I)     (Instr. 4)	7. Nature of      Indirect      Beneficial      Ownership     (Instr. 4)
			Code	V	Amount	A/D	Price
Common Stock(1)	03/14/2003		S		2,500	D	$19.54		D
Common Stock	03/14/2003		S		2,500	D	$19.61		D
Common Stock	03/14/2003		S		2,500	D	$19.75		D
Common Stock	03/14/2003		S		2,500	D	$19.76		D
Common Stock	03/14/2003		S		5,000	D	$19.85		D
Common Stock	03/14/2003		S		2,500	D	$20		D
Common Stock	03/14/2003		S		2,500	D	$20.03		D
Common Stock	03/14/2003		S		1,500	D	$20.10		D
Common Stock	03/14/2003		S		2,500	D	$20.15		D
Common Stock	03/14/2003		S		200,000	D	$20.17		D
Common Stock	03/14/2003		S		7,500	D	$20.20		D
Common Stock	03/14/2003		S		3,500	D	$20.25		D
Common Stock	03/14/2003		S		3,000	D	$20.35		D
Common Stock	03/14/2003		S		7,500	D	$20.40		D
Common Stock	03/14/2003		S		2,500	D	$20.51		D
Common Stock	03/14/2003		S		2,000	D	$20.55	3,931,309	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security     (Instr. 3)

2. Conver-     sion or     Exercise     Price of     Deri-     vative     Security

3. Transaction Date (Month/ Day/ Year)

3A. Deemed Execution Date, if any (Month/ Day/ Year)

4. Transaction Code     (Instr.8)

5. Number of Derivative     Securities Acquired (A)     or Disposed Of (D)     (Instr. 3, 4 and 5)

6. Date Exercisable(DE) and     Expiration Date(ED)     (Month/Day/Year)

7. Title and Amount of     Underlying Securities     (Instr. 3 and 4)

8. Price     of     Derivative     Security     (Instr.5)

9. Number of     Derivative     Securities     Beneficially     Owned     Following     Reported     Transaction(s)     (Instr.4)

10. Owner- ship Form of Deriv- ative Securities: Direct (D) or Indirect (I) (Instr.4)

11. Nature of       Indirect       Beneficial       Ownership       (Instr.4)

Code

V

A

D

DE

ED

Title

Amount or Number of Shares

Explanation of Responses:

Note: 1 All sales are made pursuant to the divestiture requirements of the July 12, 2002 Decision and Order of the Federal Trade Commission In the Matter of Amgen Inc. and Immunex Corporation.

By:	Date:
/s/ Richard D. Nanula	03/17/2003
Richard D. Nanula, Executive Vice President, Finance, Strategy and Communications and Chief Financial Officer
** Signature of Reporting Person	SEC 1474 (9-02)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

-----END PRIVACY-ENHANCED MESSAGE-----